CNS Drug Development

NeurOp's CNS drug development pipeline is comprised of NMDA-based compounds for the treatment of serious disorders. Our most advanced compounds for major depression and ischemia demonstrate efficacy in animal models with no apparent toxicity at therapeutic doses. The chart below shows the progress toward CNS drug development and our goal of placing a drug candidate in human clinical trials.

NeurOp's pipeline chart of central nervous system (CNS) treatments for depression, ischemia and other disorders.